All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Multiple sclerosis (MS) is a degenerative neurological disease of chronic nature \[[@pone.0159129.ref001], [@pone.0159129.ref002]\], often with unpredictable course \[[@pone.0159129.ref003]\]. MS cause both healthcare use and reduction of work capacity \[[@pone.0159129.ref004], [@pone.0159129.ref005]\]. For estimates of the economic burden of a disease, cost-of-illness (COI) studies are often implemented \[[@pone.0159129.ref006]\] which is also the case for MS \[[@pone.0159129.ref007]\]. There are several literature reviews of COI of MS, however, they either were published before year 2006 \[[@pone.0159129.ref008]--[@pone.0159129.ref011]\], focused on specific geographical areas \[[@pone.0159129.ref012], [@pone.0159129.ref013]\], were limited to intangible costs due to MS \[[@pone.0159129.ref014]\], or focused on specific treatment or drugs \[[@pone.0159129.ref015], [@pone.0159129.ref016]\]. In addition, a series of studies by Karampampa and colleagues \[[@pone.0159129.ref017]\] are now available that were not published before the two most recent literature reviews \[[@pone.0159129.ref007], [@pone.0159129.ref018]\]. There is, thus, a need for an updated systematic review of COI of MS. Important methodological aspects of COI studies that are essential to consider in systematic reviews include: the perspective of the analysis (e.g., societal), the scope of costs measured (e.g., direct, indirect, and intangible costs), the use of an incidence-based approach (including patients from time of disease onset or disease diagnosis) or prevalence approach (including patients at all stages of the disease) \[[@pone.0159129.ref019]\], as well as any other targeting of patients (such as including only those with relapsing-remitting MS). Another important consideration is whether a COI study uses a top down (TD) or a bottom up (BU) approach \[[@pone.0159129.ref004]\]. The latter concerns if estimates of costs are based on patient reports (BU) or on other types of information, e.g., from administrative registers of costs (TD).

Direct costs include inpatient care, outpatient care, drugs, diagnostics, surgical interventions, nursing care, social services, and patients´ travel costs in order to get to health care. Indirect costs are losses of production due to short- or long-term sickness absence, disability pension (in some countries called early retirement on medical grounds or incapacity benefit), early old-age pension due to health problems, permanent losses due to premature death, and sometimes time spent by next of kin to care for the patient. Intangible costs concern humanitarian losses due to, for instance, pain, anxiety, and suffering. It has been reported that the economic burden of MS includes medical and non-medical direct costs, indirect costs from increased morbidity, early mortality, and impact on family and friends, and intangible costs \[[@pone.0159129.ref020]\].

TD calculations usually rely on population-based data for a specific diagnosis and associated resource use and are often restricted to hospital admissions, reductions in productive work, and other resource use that can be identified in registers. BU calculations are commonly based on enquiries to individuals having the disease, and may thus include questions on e.g., informal care and transportation not often found in registers. The results of a BU study can start from a subpopulation and be extrapolated to the total population.

This variation in methods used in COI studies makes comparison of results between studies difficult, and concerns have been raised of the generalizability of results, also in the MS context \[[@pone.0159129.ref009], [@pone.0159129.ref021]\]. Thus, the aim of this systematic review was to compare COI estimates for MS between studies, overall and by level of severity of MS, and to examine cost drivers for the estimates, emphasizing studies with results that were generalizable to all patients with MS in the population of e.g., a country. To do this, patterns in methods used for estimating the COI of MS needed to be explored to enhance comparisons between studies.

Methods {#sec006}
=======

We conducted a systematic review following the PRISMA statement \[[@pone.0159129.ref022]\], including the following steps. Published studies on COI of MS were searched in PubMed with a supplementary search in the Health Economic Evaluations Database (HEED) for additional studies. The search terms used were Multiple Sclerosis AND (costs OR cost of illness OR economic costs OR economic burden OR economic impact OR economic status OR economic deprivation OR economic pressure OR burden of disease OR social consequences), limited to studies published in English between January 1969 to January 24^th^ 2014. The search strategy using the term "Multiple sclerosis" in combination with other search terms in separate searches resulted in a total of 2,621 studies, of which 1,326 studies remained after excluding duplicates ([Fig 1](#pone.0159129.g001){ref-type="fig"}). Full-text versions of articles were reviewed independently by OE and AN, and were retrieved if at least one of the reviewers considered the study to be relevant. Reference lists of eligible articles were hand searched for additional studies. The flow chart covering the search of literature is described in [Fig 1](#pone.0159129.g001){ref-type="fig"}.

![Flow chart.](pone.0159129.g001){#pone.0159129.g001}

Criteria were used for inclusion of studies, where any disagreement between reviewers was solved by discussions among the authors to reach consensus. The inclusion criteria were: research published in English in a peer reviewed journal, containing information on prevalence- or incidence-based cost data for MS, from OECD-countries. Intangible costs were not considered in this review. This resulted in 74 abstracts identified as possible relevant studies. Three additional publications were found through hand search in the identified reviews, resulting in a total of 77 studies that were examined in full text.

To identify relevant publications for inclusion in the mapping of COI studies on MS, the 77 identified publications were assessed in full-text for relevance. Twenty-nine of the studies did not meet the inclusion criteria, and reasons for exclusion were: three studies based on compensation data, twelve reviews, seven extrapolations, two summaries of previous studies, and one drug intervention study, as well as three studies without cost data and one in another language than English. Thus, 48 publications met our inclusion criteria and these were mapped by two authors \[OE, AN\] according to how methodological approaches were implemented: cost components included, TD or BU approach, incidence or prevalence approach.

Among the included studies, an additional assessment was performed by OE and AN to identify a sub-sample of publications with similar methodology that enabled comparisons of study results. Twenty-nine publications, with similar methodology and providing the information needed, was identified, i.e., studies having a societal perspective approach, including both direct and indirect costs, using human capital approach for indirect costs, and providing comprehensive data on number of patients, time-period studied, currency, and year of price level. Reason for not being included in this sub-sample is provided in [S1 Table](#pone.0159129.s001){ref-type="supplementary-material"}. Data on study characteristics and included cost categories were extracted from the 29 studies. In order to compare study results, costs per patient (overall and by severity of MS) were transformed using Purchasing Power Parities (PPP) for Gross domestic product to USD \[[@pone.0159129.ref023]\]. The cost data of studies using year of price level before 2011 were inflated by 1 percent annually in order to calculate a common end value for the year 2011. In two of the included studies \[[@pone.0159129.ref024], [@pone.0159129.ref025]\], results were presented in an alternate currency (Euro for non-Euro countries) and recalculations based on the exchange rates given in the articles were made in order to follow the principle of using PPP for each country. In two other studies \[[@pone.0159129.ref026], [@pone.0159129.ref027]\], exchange rates were not reported, why the PPP rate for the EU area was chosen although this concerned non-euro countries. For studies not presenting annual costs, transformations were made to 12 months basis, assuming that there were no seasonal variations in resource use.

The level of MS disability can be evaluated and presented according to the Expanded Disability Status Scale (EDSS), ranging from 0 (normal) to 10 (death due to MS) \[[@pone.0159129.ref028]\]. Thus, for further comparison, data on costs for patients with different levels of severity were extracted from twelve publications reporting costs by EDSS. The costs for different levels of EDSS were transformed and inflated to 2011 values, and were furthermore compared as costs ratios where the categorization of EDSS I of each study was the comparator of EDSS II and III for the same study.

Results {#sec007}
=======

After exclusion of duplicates, 1,326 studies remained, and applications of criteria resulted in 77 studies examined in full-text. A total of 29 studies were excluded before the final version of the mapping, i.e., 48 included studies. \[[@pone.0159129.ref001]--[@pone.0159129.ref005], [@pone.0159129.ref024]--[@pone.0159129.ref027], [@pone.0159129.ref029]--[@pone.0159129.ref067]\], of which 42 studies were categorized as mainly using a BU approach. The traditional TD approach based on register data was used in the remaining six studies ([Table 1](#pone.0159129.t001){ref-type="table"}). Five studies were categorized as examining a special aspect, i.e., incidence for one year \[[@pone.0159129.ref062]\], intangible costs \[[@pone.0159129.ref063]\], the cost of relapse \[[@pone.0159129.ref064], [@pone.0159129.ref067]\], and cost for MS-patients with spasticity \[[@pone.0159129.ref060]\].

10.1371/journal.pone.0159129.t001

###### Mapping of relevant studies (n = 48) regarding having a bottom-up or top-down approach and by type of costs included in the analyses.
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                                Mainly bottom up                                                                                           Mainly top down
  ----------------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  **Direct costs**              Berto \[[@pone.0159129.ref002]\], 2011                                                                     Gilden \[[@pone.0159129.ref065]\], 2011
                                Bourdette \[[@pone.0159129.ref029]\], 1993                                                                 
                                Patti \[[@pone.0159129.ref030]\], 2011                                                                     
                                Carton \[[@pone.0159129.ref031]\], 1998                                                                    
  **Indirect costs**            Coleman \[[@pone.0159129.ref032]\] 2013                                                                    
  **Direct + indirect costs**   Amato \[[@pone.0159129.ref003]\], 2002                                                                     Asche \[[@pone.0159129.ref001]\], 1997
                                Auty \[[@pone.0159129.ref033]\], 1998[\*](#t001fn001){ref-type="table-fn"}                                 Henriksson \[[@pone.0159129.ref004]\], 1998
                                Berg \[[@pone.0159129.ref025]\], 2006[\*](#t001fn001){ref-type="table-fn"}                                 Jennum \[[@pone.0159129.ref024]\], 2012[\*](#t001fn001){ref-type="table-fn"}
                                Casado \[[@pone.0159129.ref034]\], 2006[\*](#t001fn001){ref-type="table-fn"}                               Blumhardt \[[@pone.0159129.ref066]\], 1996
                                Dusankova \[[@pone.0159129.ref026]\], 2012[\*](#t001fn001){ref-type="table-fn"}                            
                                Grima \[[@pone.0159129.ref005]\], 2000                                                                     
                                Henriksson \[[@pone.0159129.ref035]\], 2001[\*](#t001fn001){ref-type="table-fn"}                           
                                Holmes \[[@pone.0159129.ref036]\], 1995                                                                    
                                Johansson \[[@pone.0159129.ref037]\], 2012[\*](#t001fn001){ref-type="table-fn"}                            
                                Karampampa \[[@pone.0159129.ref038]--[@pone.0159129.ref042]\], 2012[\*](#t001fn001){ref-type="table-fn"}   
                                Karampampa \[[@pone.0159129.ref043]\], 2013[\*](#t001fn001){ref-type="table-fn"}                           
                                Kobelt \[[@pone.0159129.ref044]--[@pone.0159129.ref052]\], 2006[\*](#t001fn001){ref-type="table-fn"}       
                                Kobelt \[[@pone.0159129.ref053]\], 2009[\*](#t001fn001){ref-type="table-fn"}                               
                                McCrone \[[@pone.0159129.ref054]\], 2008[\*](#t001fn001){ref-type="table-fn"}                              
                                Murphy \[[@pone.0159129.ref055]\], 1998                                                                    
                                Oleen-Burkey \[[@pone.0159129.ref056]\], 2012                                                              
                                Orlewska \[[@pone.0159129.ref057]\], 2005[\*](#t001fn001){ref-type="table-fn"}                             
                                Palmer \[[@pone.0159129.ref058]\], 2013[\*](#t001fn001){ref-type="table-fn"}                               
                                Reese \[[@pone.0159129.ref059]\], 2011[\*](#t001fn001){ref-type="table-fn"}                                
                                Svendsen \[[@pone.0159129.ref027]\], 2012[\*](#t001fn001){ref-type="table-fn"}                             
                                Svensson \[[@pone.0159129.ref060]\], 2013                                                                  
                                Taylor \[[@pone.0159129.ref061]\], 2007[\*](#t001fn001){ref-type="table-fn"}                               
  **Special aspect**            Asche \[[@pone.0159129.ref062]\], 2010                                                                     Parisé \[[@pone.0159129.ref067]\], 2013
                                Casado \[[@pone.0159129.ref063]\], 2007                                                                    
                                Zettl \[[@pone.0159129.ref064]\], 2013                                                                     

\* Included in the further analysis displayed in [Table 2](#pone.0159129.t002){ref-type="table"}

Twenty-nine studies of those included in the mapping were further compared regarding cost of MS \[[@pone.0159129.ref024]--[@pone.0159129.ref027], [@pone.0159129.ref033]--[@pone.0159129.ref035], [@pone.0159129.ref037]--[@pone.0159129.ref054], [@pone.0159129.ref057]--[@pone.0159129.ref059], [@pone.0159129.ref061]\]. All these 29 studies used a prevalence approach and all studies but one \[[@pone.0159129.ref024]\] mainly used a BU approach ([Table 2](#pone.0159129.t002){ref-type="table"}). There were 17 countries covered by the included studies. Ten of the studies were conducted by the same Swedish group of authors \[[@pone.0159129.ref025], [@pone.0159129.ref044]--[@pone.0159129.ref053]\] and seven studies were done by another group with connections to Sweden \[[@pone.0159129.ref037]--[@pone.0159129.ref043]\], resulting in that 17 (59%) of the studies were conducted by two Swedish research centers.

10.1371/journal.pone.0159129.t002

###### Summary of each of the 29 studies included in the analysis of comparing costs.
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  Reference                                                               Study population                                                                                                   Cost-of-illness methodology                                                                         Cost estimates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  **Auty** \[[@pone.0159129.ref033]\] 1998, Canada                        MS patients recruited from MS centers (n = 198; response rate not given)                                           MS diagnosis according to Poser criteria                                                            Bottom up, Prevalence            Patients and family via Case Report Form; Clinical charts and summaries on medical history; Price lists; Market prices; Statistics on wages     Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical Mild \$2,250; Moderate \$1,969; Severe \$7,233                               Mean annual cost per patient:                                                      Mean annual cost per patient \$29,109
                                                                          EDSS ≤2.5 (n = 62); EDSS 3--6 (n = 68); EDSS ≥6.5 (n = 68)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Direct non-medical Mild \$912; Moderate \$1,663; Severe \$7,787                                                           Mild \$11,360; Moderate \$18,068; Severe \$22,002                                  Mild \$14,522; Moderate \$21,698; Severe \$37,024
  **Berg** \[[@pone.0159129.ref025]\] 2006, Sweden                        MS patients recruited from patients´ organization register (n = 1,339, 64% response rate)                          MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists; Personal communication; Statistics on wages                                                            Direct health care costs, direct non-medical costs, indirect costs, intangible costs                                            Mean annual cost per patient: Direct medical €15,186                                                                      Mean annual cost per patient €17,151                                               Mean annual cost per patient €53,601
                                                                          EDSS 0--3 (29%); EDSS 4--6.5 (45.5%); EDSS 7--9 (25.2%)                                                            RRMS Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                  Direct non-medical €21,264                                                                                                                                                                                   
  **Casado** \[[@pone.0159129.ref034]\] 2006, Spain                       MS patients recruited from one MS center (n = 200, 44% response rate)                                              n/a                                                                                                 Bottom up, Prevalence            Patients via questionnaire; Inpatient records; Price lists from health care; Statistics on wages; Market prices for pharmaceuticals             Direct costs, indirect costs, informal care costs                                                                               Mean annual cost per patient €15,860                                                                                      Mean annual cost per patient €8,412                                                Mean annual cost per patient €24,272
                                                                          EDSS 0 (n = 23); EDSS 1--3 (n = 107); EDSS 3.5--5.5 (n = 42); EDSS 6--7 (n = 17); EDSS 7.5--9.5 (n = 11)           RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Stage 1 €8,706; Stage 2 €12,221; Stage 3 €18,724; Stage 4 €24,037; Stage 5 €37,062                                        Stage 1 €5,621; Stage 2 €6,616; Stage 3 €9,596; Stage 4 €17,161; Stage 5 €15,779   Stage 1 €14,327; Stage 2 €18,837; Stage 3 €27,869; Stage 4 €41,198; Stage 5 €52,841
  **Blahova Dusankova** \[[@pone.0159129.ref026]\] 2012, Czech Republic   MS patients recruited from MS centers (n = 1,027, 89% response rate)                                               Diagnosis of MS according to the 2005 revised McDonald criteria                                     Bottom up, Prevalence            Patients via questionnaire; Medical records; Price lists from health care                                                                       Direct health care costs, direct non-medical costs, indirect costs                                                              Mean annual cost per patient: Direct medical €6,296                                                                       Mean annual cost per patient €5,519                                                Mean annual cost per patient €12,272
                                                                          EDSS 0--3.5 (n = 579); EDSS 4--6.5 (n = 246); EDSS 7--9.5 (n = 87)                                                 RRMS, SPMS, PPMS/RPMS                                                                                                                                                                                                                                                                                                                                                                                                Direct non-medical €457                                                                                                                                                                                      
  **Henriksson** \[[@pone.0159129.ref035]\] 2001, Sweden                  MS patients recruited from one MS center (n = 413, 76% response rate)                                              Definite clinical MS according to Poser criteria                                                    Bottom up, Prevalence            Patients via questionnaire; Medical records; Price lists from health care; Community price lists; Personal communication; Statistics on wages   Direct costs, indirect costs, intangible costs                                                                                  Annual cost per patient €35,728                                                                                           Annual cost per patient €17,518                                                    Annual cost per patient €53,246
                                                                          EDSS ≤3 (n = 126); EDSS 3.5--6 (n = 121); EDSS ≥6.5 (n = 162)                                                      RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Johansson** \[[@pone.0159129.ref037]\] 2012, France                   MS patients recruited from MS centers (n = 248, 61% response rate)                                                 MS diagnosis (ICD-10; G35, ICD-9; 340)                                                              Bottom up, Prevalence            Patients via questionnaire; Price lists from health care and insurance payer; Published literature; Statistics on wages                         Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical €15,445; Mild €13,242; Moderate €19,845; Severe €19,491                      Mean annual cost per patient €3,022                                                Mean annual cost per patient €20,738
                                                                          EDSS 0--3 (n = 164); EDSS 4--6.5 (n = 69); EDSS 7--9 (n = 11)                                                      RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Direct non-medical €2,271; Mild €1,051; Moderate €3,967; Severe €16,049                                                   Mild €1,715; Moderate €5,440; Severe €8,448                                        Mild €16,009; Moderate €29,252; Severe €43,988
  **Karampampa** \[[@pone.0159129.ref038]\] 2012, Canada                  MS patients recruited from MS centers (n = 241, response rate not given)                                           MS diagnosis (ICD-10; G35, ICD-9; 340)                                                              Bottom up, Prevalence            Patients via questionnaire; Price lists from public sources; Price lists from private providers; Statistics on wages                            Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical Mild \$19,837; Moderate \$14,058; Severe \$9,478                             Mean annual cost per patient                                                       Mean annual cost per patient \$37,672
                                                                          EDSS 0--3 (n = 146); EDSS 4--6.5 (n = 89); EDSS 7--9 (n = 5)                                                       RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Direct non-medical Mild \$3,848; Moderate \$12,712; Severe \$44,022                                                       Mild \$7,151; Moderate \$19,853; Severe \$24,480                                   Mild \$30,836; Moderate \$46,622; Severe \$77,981
  **Karampampa** \[[@pone.0159129.ref039]\] 2012, Spain                   MS patients recruited from MS centers (n = 324, 99% response rate)                                                 MS diagnosis (ICD-10; G35, ICD-9; 340)                                                              Bottom up, Prevalence            Patients via questionnaire; Published literature; Price lists from public sources; Statistics on wages                                          Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical Mild €14,594; Moderate €18,924; Severe €15,845                               Mean annual cost per patient                                                       Mean annual cost per patient €29,401
                                                                          EDSS 0--3 (n = 209); EDSS 4--6.5 (n = 105); EDSS 7--9 (n = 10)                                                     RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Direct non-medical Mild €1,386; Moderate €12,441; Severe €22,910                                                          Mild €4,680; Moderate €12,583; Severe €20,592                                      Mild €20,659; Moderate €43,948; Severe €59,347
  **Karampampa** \[[@pone.0159129.ref040]\] 2012, Germany                 MS patients recruited from MS centers (n = 244, 63% response rate)                                                 MS diagnosis (ICD-10; G35, ICD-9; 340)                                                              Bottom up, Prevalence            Patients via questionnaire; Price lists from public sources; Published literature; Statistics on wages                                          Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical Mild €16,954; Moderate; €17,841; Severe €30,348                              Mean annual cost per patient                                                       Mean annual cost per patient
                                                                          EDSS 0--3 (n = 164); EDSS 4--6.5 (n = 69); EDSS 7--9 (n = 11)                                                      RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Direct non-medical Mild €1,163; Moderate €12,373; Severe €22,926                                                          Mild €3,057; Moderate €9,710; Severe €10,996                                       Mild €21,174; Moderate €39,923; Severe €64,270
  **Karampampa** \[[@pone.0159129.ref041]\] 2012, Italy                   MS patients recruited from MS centers (n = 251, 83% response rate)                                                 MS diagnosis (ICD-10; G35, ICD-9; 340)                                                              Bottom up, Prevalence            Patients via questionnaire; Price lists from public sources; Regional tariffs; Published literature; Statistics on wages                        Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical Mild €21,418; Moderate €30,507; Severe €13,646                               Mean annual cost per patient                                                       Mean annual cost per patient €26,041
                                                                          EDSS 0--3 (n = 203); EDSS 4--6.5 (n = 44); EDSS 7--9 (n = 4)                                                       RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Direct non-medical Mild €447; Moderate €5,634; Severe €15,826                                                             Mild €596; Moderate €5,185; Severe €10,120                                         Mild €22,461; Moderate €41,327; Severe €39,592
  **Karampampa** \[[@pone.0159129.ref042]\] 2012, UK                      MS patients recruited from MS centers (n = 194, 33% response rate)                                                 MS diagnosis (ICD-10; G35, ICD-9; 340)                                                              Bottom up, Prevalence            Patients via questionnaire; Price lists from public sources; Published literature; Statistics on wages                                          Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical Mild £6,714; Moderate £8,101; Severe £6,059                                  Mean annual cost per patient                                                       Mean annual cost per patient £21,512
                                                                          EDSS 0--3 (n = 77); EDSS 4--6.5 (n = 110); EDSS 7--9 (n = 7)                                                       RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Direct non-medical Mild £1,913; Moderate £10,299; Severe £41,242                                                          Mild £3,214; Moderate £7,494; Severe £11,717                                       Mild £11,841; Moderate £25,894; Severe £59,018
  **Karampampa** \[[@pone.0159129.ref043]\] 2013, The Netherlands         MS patients recruited from MS centers (n = 263, response rate not given)                                           MS diagnosis (ICD-10; G35, ICD-9; 340)                                                              Bottom up, Prevalence            Patients via questionnaire; Price lists; Published literature; Statistics on wages                                                              Direct medical costs, direct non-medical costs, indirect costs                                                                  Mean annual cost per patient: Direct medical €12,265; Mild €11,274; Moderate €13,668; Severe €13,978                      Mean annual cost per patient €20,284                                               Mean annual cost per patient €47,173
                                                                          EDSS 0--3 (n = 122); EDSS 4--6.5 (n = 112); EDSS 7--9 (n = 29)                                                     RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     Direct non-medical €14,624; Mild €4,951; Moderate €14,967; Severe €52,303                                                 Mild €14,714; Moderate €22,421; Severe €34,188                                     Mild €30,938; Moderate €51,056; Severe €100,469
  **Kobelt** \[[@pone.0159129.ref044]\] 2006, The Netherlands             MS patients recruited from MS centers (n = 1,549, 52% response rate)                                               MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Statistics on wages; WTP/QALY                                                         Direct medical costs, direct non-medical costs, indirect costs including friction costs, intangible costs                       Mean annual cost per patient: Direct medical €8,371                                                                       Mean annual cost per patient €13,476                                               Mean annual cost per patient €29,423
                                                                          EDSS 0--3 (47.9%); EDSS 4--6.5 (39.6%); EDSS 7--9.5 (11.2%)                                                        RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non---medical €7,576                                                                                               *Friction cost €611*                                                               *Friction cost €16*,*600*
  **Kobelt** \[[@pone.0159129.ref045]\] 2006, Switzerland                 MS patients recruited from patients´ organization register (n = 1,101, 44% response rate)                          MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Personal communication; Statistics on wages; WTP/QALY                                 Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient: Direct medical €11,237                                                                      Mean annual cost per patient €15,928                                               Mean annual cost per patient €41,873
                                                                          EDSS 0--3 (38.3%); EDSS 4--6.5 (35.8%); EDSS 7--9 (22.8%); EDSS 8--9 (14.3%)                                       RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical €14,708                                                                                                                                                                                   
  **Kobelt** \[[@pone.0159129.ref046]\] 2006, UK                          MS patients recruited from patients´ organization register (n = 2,048, 16% response rate)                          MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Published literature; Market prices; Statistics on wages; WTP/QALY                    Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient: Direct medical £6,810                                                                       Mean annual cost per patient £11,174                                               Mean annual cost per patient £30,263
                                                                          EDSS 0--3 (21.3%); EDSS 4--6.5 (59.6%); EDSS 7--9 (19.1%)                                                          RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical £12,298                                                                                                                                                                                   
  **Kobelt** \[[@pone.0159129.ref047]\] 2006, Austria                     MS patients recruited from patients´ organization register (n = 1,019, 34% response rate)                          MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Personal communication; Statistics on wages; WTP/QALY                                 Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient: Direct medical €17,302                                                                      Mean annual cost per patient €14,657                                               Mean annual cost per patient €40,309
                                                                          EDSS 0--3 (40.6%); EDSS 4--6.5 (35.6%); EDSS 7--9.5 (22.2%)                                                        RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical €8,351                                                                                                                                                                                    
  **Kobelt** \[[@pone.0159129.ref048]\] 2006, Germany                     MS patients recruited from MS centers (53%) and from one database (47%) (n = 2,793, 38% response rate)             MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Personal communication; Market prices; Statistics on wages; WTP/QALY                  Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient: Direct medical €17,165                                                                      Mean annual cost per patient €16,911                                               Mean annual cost per patient €39,998
                                                                          EDSS 0--3 (47.4%); EDSS 4--6.5 (35.6%); EDSS 7--9.5 (12%)                                                          RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical €5,922                                                                                                                                                                                    
  **Kobelt** \[[@pone.0159129.ref049]\] 2006, Italy                       MS patients recruited from patients´ organization register (n = 921, 52% response rate)                            MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Personal communication; Statistics on wages; WTP/QALY                                 Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient: Direct medical €11,111                                                                      Mean annual cost per patient €11,310                                               Mean annual cost per patient €38,845
                                                                          EDSS 0--3 (31.3%); EDSS 4--6.5 (47.2%); EDSS 7--9.5 (19.6%)                                                        RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical €16,424                                                                                                                                                                                   
  **Kobelt** \[[@pone.0159129.ref050]\] 2006, Belgium                     MS patients recruited from MS centers (n = 799, 38% response rate)                                                 MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Statistics on wages; WTP/QALY                                                         Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient: Direct medical €12,020                                                                      Mean annual cost per patient €11,604                                               Mean annual cost per patient €32,466
                                                                          EDSS 0--3.5 (45.5%); EDSS 4--6.5 (32.2%); EDSS 7--9.5 (19.7%)                                                      RRMS; Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical €8,842                                                                                                                                                                                    
  **Kobelt** \[[@pone.0159129.ref051]\] 2006, Spain                       MS patients recruited from patients´ organization register (n = 1,848, 32% response rate)                          MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Statistics on wages; WTP/QALY                                                         Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient: Direct medical €12,142                                                                      Mean annual cost per patient €8,775                                                Mean annual cost per patient €33,456
                                                                          EDSS 0--3 (36.1%); EDSS 4--6.5 (44.8%); EDSS 7--9 (17.7%)                                                          RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                 Direct non-medical €12,540                                                                                                                                                                                   
  **Kobelt** \[[@pone.0159129.ref052]\] 2006, US                          MS patients randomly selected from one register (n = 1,909, 48% response rate)                                     MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from public sources; Personal communication; Statistics on wages; WTP/QALY                              Direct medical costs, direct non-medical costs, indirect costs, intangible costs                                                Mean annual cost per patient \$29,634                                                                                     Mean annual cost per patient \$17,581                                              Mean annual cost per patient \$47,215
                                                                          EDSS ≤3.5 (34.8%); EDSS 4--6 (42.7%); EDSS ≥6.5 (22.1%)                                                            PPMS, RRMS, SPMS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Kobelt** \[[@pone.0159129.ref053]\] 2009, France                      MS patients recruited from patients´ organization register (n = 1,355, 34% response rate)                          MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Statistics on wages                                                                   Direct costs, indirect costs                                                                                                    Mean annual cost per patient €23,654                                                                                      Mean annual cost per patient €20,730                                               Mean annual cost per patient €44,384
                                                                          EDSS 0--3 (n = 529); EDSS 4--5 (n = 315); EDSS 6--7 (n = 354); EDSS 8--9 (n = 136)                                 RRMS, Progressive MS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **McCrone** \[[@pone.0159129.ref054]\] 2008, UK                         MS patients recruited from patients´ organization register (n = 1,942, 49% response rate)                          MS according to patients' own estimates                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Published literature; Statistics on wages                                             Direct costs (service costs), indirect costs (lost employment)                                                                  Mean 6.monthly cost £8,397                                                                                                Mean 6.monthly cost £4,240                                                         Mean 6.monthly cost £12,655
                                                                          GNDS 0--9 (n = 192); GNDS 10--19 (n = 694); GNDS 20--29 (n = 734); GNDS 30--39 (n = 265); GNDS ≥40 (n = 43)        RRMS, SPMS, PPMS, Benign MS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  **Orlewska** \[[@pone.0159129.ref057]\] 2005, Poland                    MS patients recruited from MS centers (n = 148, response rate not given)                                           Definite MS according to Poser criteria                                                             Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Market prices; Statistics on wages                                                    Direct costs, indirect costs                                                                                                    Mean cost per patient per 5 months                                                                                        Mean cost per patient per 5 months                                                 Mean cost per patient per 5 months
                                                                          EDSS \<3.5 (n = 57); EDSS 4--6 (n = 56); EDSS \>6.5 (n = 35)                                                       RRMS, SPMS                                                                                                                                                                                                                                                                                                                                                                                                           Mild 4,069 PLN; Moderate 5,399 PLN; Severe 6,010 PLN                                                                      Mild 6,886 PLN; Moderate 10,204 PLN; Severe 12,454 PLN                             Mild 10,954 PLN; Moderate 15,603 PLN; Severe 18,464 PLN
  **Palmer** \[[@pone.0159129.ref058]\] 2013, Australia                   MS patients recruited from register (n = 712, 28% response rate)                                                   Self-reported MS                                                                                    Bottom up, Prevalence            Patients via questionnaire and diary; Price lists from health care; Statistics on wages                                                         Direct personal costs, direct community/ governmental costs, nursing home and equivalent costs, informal care, indirect costs   Mean annual cost per patient: Personal AUD 3,697; Community AUD 10,721; Nursing home AUD 4,384; Informal care AUD 6,857   Mean annual cost per patient AUD 23,286                                            Mean annual cost per patient AUD 48,945
                                                                          EDSS 1--3; EDSS 4--6; EDSS 6.5--9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  **Reese** \[[@pone.0159129.ref059]\] 2011, Germany                      MS patients recruited from one MS center (n = 144, 77% response rate)                                              Definite MS according to McDonald diagnostic criteria                                               Bottom up, Prevalence            Patients via questionnaire; Price lists from health care; Price lists from companies; Published literature; Statistics on wages                 Direct medical costs, indirect costs                                                                                            Mean cost per patient per 3 months €5,483                                                                                 Mean cost per patient per 3 months €4,846                                          Mean cost per patient per 3 months €10, 329
                                                                          EDSS 0--1.5; EDSS 2--3.5; EDSS 4--5.5; ESSS 6--8.5                                                                 RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Svendsen** \[[@pone.0159129.ref027]\] 2012, Norway                    MS patients from one patient organization register and data from national registers (n = 423, 80% response rate)   Definite MS according to Poser criteria                                                             Bottom up/Top down, Prevalence   Patients via questionnaires; Price lists from health care; Medical records; Registers; Statistics on cost of labor                              Direct costs, indirect costs                                                                                                    Annual cost to the society €171,387,000                                                                                   Annual cost to the society €,267,588,000                                           Mean annual cost per patient €65,037
                                                                          EDSS 0--3 (43.5%); EDSS 4--6.5 (43%); EDSS 7--9 (13.5%)                                                            RRMS, PPMS/SPMS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Annual cost to the society €438,975,000
  **Taylor** \[[@pone.0159129.ref061]\] 2007, Australia                   MS patients recruited from one MS center (n = 100, response rate not given)                                        Definite MS according to Poser and Rose criteria, and reclassified according to McDonald criteria   Bottom up, Prevalence            Patients via questionnaire; Data sources for costs not given                                                                                    Direct costs, indirect costs                                                                                                    Mean annual cost per patient AU\$20,396                                                                                   Mean annual cost per patient AU\$15,085                                            Mean annual cost per patient AU\$35,481
                                                                          EDSS 0--2.5 (n = 30); EDSS 3--4.5 (n = 29); EDSS 5--6.5 (n = 22); EDSS ≥7 (n = 19)                                 RRMS, SPMS, PPMS                                                                                                                                                                                                                                                                                                                                                                                                     EDSS 0--2.5 AU\$18,568; EDSS 3--4.5 AU\$15,504; EDSS 5--6.5 AU\$20,159; EDSS ≥ 7 AU\$31,025                                                                                                                  
  **Jennum** \[[@pone.0159129.ref024]\] 2012, Denmark                     MS patients from a national database (n = 10,849)                                                                  MS diagnosis (ICD-10)                                                                               Top down, Prevalence             Registers on use and costs of health care; Social statistics data                                                                               Direct costs, indirect costs, social transfers                                                                                  Mean annual cost per patient €3,465                                                                                       Mean annual cost per patient €11,110                                               Mean annual cost per patient €14,575

The cost categories that were most frequently reported in the 29 included studies are presented in [Table 3](#pone.0159129.t003){ref-type="table"}. All studies included direct costs for inpatient care and costs for drugs, and all studies but one \[[@pone.0159129.ref058]\] explicitly reported about including direct costs for outpatient care. Costs related to specialists other than those mentioned were, e.g., opticians, speech therapists, psychiatrists, and acupuncturists. The inclusion of other direct costs varied between studies. Among the 29 studies, 25 studies included costs for informal care, 21 reported nursing home costs, and 22 included home help services. Concerning indirect costs, all studies reported short-term work absence, while long-term and permanent reductions in productive work were reported in most, but not all, studies. Permanent reductions in productive work were commonly called early retirement due to MS in the studies ([Table 3](#pone.0159129.t003){ref-type="table"}). Only one study included indirect costs due to premature death \[[@pone.0159129.ref027]\], while another study stated it was excluded since there was no higher risk of premature death for patients with MS compared to the rest of the population \[[@pone.0159129.ref035]\]. Costs that were less frequently reported in the studies were e.g., child care, social services and workplace adaptions. As can be seen from [Table 3](#pone.0159129.t003){ref-type="table"} costs data used in the included studies were based on data with differences of levels of specification. For example, studies by Auty \[[@pone.0159129.ref033]\] and by Taylor \[[@pone.0159129.ref061]\] had few specified data, and included only short term absence as regards indirect costs, as compared to the high specifications of data and inclusion also of long term sickness absence in the studies by Kobelt \[[@pone.0159129.ref025], [@pone.0159129.ref044]--[@pone.0159129.ref051]\] and Karampampa \[[@pone.0159129.ref037]--[@pone.0159129.ref043]\]. The difference of estimated cost per patient corresponded to almost 50%, i.e. 28 575 USD (average for Auty and Taylor) compared to 42 567 USD (average for Kobelt and Karampampa).

10.1371/journal.pone.0159129.t003

###### The most frequently reported cost categories in the 29 included studies.

The resource use indicated in the table is reported as in the original publication, there is thus a variation in the level of aggregation in information from the different sources.
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                              Auty \[[@pone.0159129.ref033]\] 1998       Berg \[[@pone.0159129.ref025]\] 2006   Casado \[[@pone.0159129.ref034]\] 2006   B Dusankova \[[@pone.0159129.ref026]\] 2012   Henriksson \[[@pone.0159129.ref035]\] 2001   Johansson \[[@pone.0159129.ref037]\] 2012   Karampampa \[[@pone.0159129.ref038]--[@pone.0159129.ref043]\] 2012--2013   Kobelt \[[@pone.0159129.ref044]--[@pone.0159129.ref053]\] 2006   McCrone \[[@pone.0159129.ref054]\] 2008   Orlewska \[[@pone.0159129.ref057]\] 2005   Palmer \[[@pone.0159129.ref058]\] 2013                                              Reese \[[@pone.0159129.ref059]\] 2011   Svendsen \[[@pone.0159129.ref027]\] 2012   Taylor \[[@pone.0159129.ref061]\] 2007     Jennum \[[@pone.0159129.ref024]\] 2012
  --------------------------- ------------------------------------------ -------------------------------------- ---------------------------------------- --------------------------------------------- -------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------- ------------------------------------------ ----------------------------------------------------------------------------------- --------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------
  Inpatient care              X                                          X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                          X                                                                                   X                                       X                                          X                                          X
  Outpatient care             X                                          X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                                                                                                              X                                       X                                          X                                          X
  Rehabilitation                                                         X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                                                          X                                          X                                                                                   X                                       X                                                                                     
  General practitioner                                                   X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                                                                                                                                                        X                                       X                                                                                     X
  Nurse                                                                  X                                                                                                                             X                                            X                                           X                                                                          X                                                                X                                                                                                                                                                                                                X                                                                                     
  Neurologist                                                            X                                                                               X                                             X                                            X                                           X                                                                          X                                                                                                                                                                                                                                         X                                       X                                                                                     
  Physiotherapist                                                        X                                                                               X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                                                                                                              X                                       X                                                                                     
  Occupational therapist                                                 X                                                                                                                             X                                            X                                           X                                                                          X                                                                                                                                                                                                                                         X                                       X                                                                                     
  Psychologist                                                           X                                                                               X                                             X                                            X                                           X                                                                          X                                                                                                                                                                                                                                         X                                       X                                                                                     
  Other specialists                                                      X                                                                               X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                                                                                                              X                                       X                                                                                     X
  Drugs                       X                                          X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                          X                                                                                   X                                       X                                          X                                          X
  Tests                       X                                          X                                      X                                        X                                                                                          X                                           X                                                                          X                                                                X                                         X                                          X                                                                                                                                                                      X                                          
  Home care/ Home visits                                                 X                                                                               X                                             X                                                                                                                                                                   X                                                                                                          X                                          X                                                                                                                           X                                                                                     
  Informal care                                                          X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                          X                                                                                                                           X                                                                                     
  Nursing home                                                           X                                                                                                                                                                          X                                           X                                                                          X                                                                X                                                                                    X                                                                                                                           X                                                                                     
  Home help                                                              X                                                                               X                                             X                                            X                                           X                                                                          X                                                                X                                                                                                                                                                                                                                                           X                                          
  Home or car modifications                                              X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                          X                                                                                   X                                       X                                          X                                          
  Walking aids                                                           X                                                                               X                                             X                                            X                                           X                                                                          X                                                                                                                                                                                                                                         X                                       X                                          X                                          
  Other investments                                                      X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                          X                                                                                   X                                       X                                          X                                          
  Transportations             X                                          X                                      X                                        X                                                                                                                                                                                                                 X                                                                                                          X                                                                                                                                                                      X                                          X                                          
  Short-term absence          X [^1^](#t003fn001){ref-type="table-fn"}   X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                                                                                                              X                                       X                                          X                                          X [^2^](#t003fn002){ref-type="table-fn"}
  Long-term absence                                                      X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X                                                                                                                              X                                       X                                                                                     X [^2^](#t003fn002){ref-type="table-fn"}
  Early retirement                                                       X                                      X                                        X                                             X                                            X                                           X                                                                          X                                                                X                                         X [^2^](#t003fn002){ref-type="table-fn"}   X [^2^](#t003fn002){ref-type="table-fn"}^,^[^3^](#t003fn003){ref-type="table-fn"}   X                                       X                                          X [^2^](#t003fn002){ref-type="table-fn"}   X [^2^](#t003fn002){ref-type="table-fn"}

^1^ days missed from work during 3 months

^2^ lost employment/unemployment/reduced labor supply

^3^ based on asking participants whether they are employed or not

Per patient costs inflated to end values for the year 2011 are presented in [Table 4](#pone.0159129.t004){ref-type="table"}. After re-calculating the costs per patient, costs were up to six times higher for the studies using the BU approach than that presented in the study using a TD approach ([Fig 2](#pone.0159129.g002){ref-type="fig"}). An analysis of linear regression showed a non-significant association (i.e., p\<0.05) between year of publication and total cost per patient (r = 0.154, p = 0,44). In comparison of the BU studies, costs per patient differed up to five times between the lowest and highest estimate. Aside from the two studies reporting the highest and lowest cost estimates, costs differed up to two times between the remaining studies.

10.1371/journal.pone.0159129.t004

###### Presentation of costs for the year 2011 after transforming costs to US dollars using Purchasing Power Parities (PPP), by inflating 1% annually.
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  First author, Publication year, Method of calculation                              Year of costing   Currency          Total direct + indirect costs   PPP rate   Total costs transformed to USD using PPP, per patient and year   Recalculated with 1% inflation rate, present value 2011
  ---------------------------------------------------------------------------------- ----------------- ----------------- ------------------------------- ---------- ---------------------------------------------------------------- ---------------------------------------------------------
  **Top down**                                                                                                                                                                                                                       
  Jennum \[[@pone.0159129.ref024]\][^1^](#t004fn001){ref-type="table-fn"} 2012       2006              DKK               108 684                         8.31       13 055                                                           13 721
  **Bottom up**                                                                                                                                                                                                                      
  Auty \[[@pone.0159129.ref033]\] 1998                                               1995              CDN dollar (\$)   29 100                          1.21       23 977                                                           28 115
  Berg \[[@pone.0159129.ref025]\][^2^](#t004fn002){ref-type="table-fn"} 2006         2004              SEK               486 354                         9.11       53 392                                                           57 243
  Casado \[[@pone.0159129.ref034]\] 2006                                             2004              Euro (€)          24 272                          0.76       31 956                                                           34 261
  Dusankova \[[@pone.0159129.ref026]\] [^3^](#t004fn003){ref-type="table-fn"} 2012   2007              Euro (€)          12 272                          0.82       14 897                                                           15 502
  Henriksson \[[@pone.0159129.ref035]\] 2001                                         1998              SEK               442 476                         9.37       47 231                                                           53 753
  Karampampa \[[@pone.0159129.ref038]\] 2012                                         2009              CAN dollar (\$)   37 672                          1.20       31 324                                                           31 953
  Karampampa \[[@pone.0159129.ref037]\] 2012                                         2009              Euro (€)          20 738                          0.86       24 180                                                           24 666
  Karampampa \[[@pone.0159129.ref041]\] 2012                                         2009              Euro (€)          26 041                          0.78       33 541                                                           34 215
  Karampampa \[[@pone.0159129.ref039]\] 2012                                         2009              Euro (€)          29 401                          0.71       41 600                                                           42 437
  Karampampa \[[@pone.0159129.ref042]\] 2012                                         2009              Pound (£)         21 512                          0.65       32 922                                                           33 583
  Karampampa \[[@pone.0159129.ref043]\] 2013                                         2011              Euro (€)          47 173                          0.83       56 719                                                           56 719
  Kobelt \[[@pone.0159129.ref044]\] 2006                                             2004              Euro (€)          29 423                          0.91       32 833                                                           34 852
  Kobelt \[[@pone.0159129.ref045]\] 2006                                             2005              CHF               64 850                          1.74       37 211                                                           39 500
  Kobelt \[[@pone.0159129.ref046]\] 2006                                             2005              Pound (£)         30 263                          0.64       47 570                                                           50 497
  Kobelt \[[@pone.0159129.ref047]\] 2006                                             2004              Euro (€)          40 309                          0.87       46 077                                                           49 401
  Kobelt \[[@pone.0159129.ref048]\] 2006                                             2004              Euro (€)          39 998                          0.90       44 592                                                           47 809
  Kobelt \[[@pone.0159129.ref049]\] 2006                                             2005              Euro (€)          38 845                          0.87       44 822                                                           47 580
  Kobelt \[[@pone.0159129.ref050]\] 2006                                             2004              Euro (€)          32 466                          0.90       36 089                                                           38 310
  Kobelt \[[@pone.0159129.ref051]\] 2006                                             2004              Euro (€)          33 456                          0.76       44 047                                                           47 225
  Koblt \[[@pone.0159129.ref052]\] 2006                                              2004              US dollar (\$)    47 215                          1.00       47 215                                                           50 621
  Kobelt \[[@pone.0159129.ref053]\] 2009                                             2007              Euro (€)          44 384                          0.89       49 661                                                           51 678
  McCrone \[[@pone.0159129.ref054]\] 2008                                            2006              Pound (£)         12 655                          0.63       40 429                                                           42 491
  Palmer \[[@pone.0159129.ref058]\] 2013                                             2010              AU dollar (\$)    48 945                          1.51       32 497                                                           32 822
  Reese \[[@pone.0159129.ref059]\] 2011                                              2009              Euro (€)          10 329                          0.81       51 254                                                           52 284
  Svendsen \[[@pone.0159129.ref027]\][^3^](#t004fn003){ref-type="table-fn"} 2012     2002              Euro (€)          65 037                          0.87       75 049                                                           82 080
  Taylor \[[@pone.0159129.ref061]\] 2007                                             2002              AU\$              35 481                          1.336      26 548                                                           29 035

^1^ transformed from EUR to DKK with exchange rate (EUR 1 = DKK 7,45) stated in article

^2^ transformed from EUR to SEK with exchange rate (EUR 1 = SEK 9,0736) stated in article

^3^ 'Euro area' used in PPP transformations, whereas no exchange rate was stated in article

![Cost per patient and year, discounted at 1% until 2011.](pone.0159129.g002){#pone.0159129.g002}

Twenty-seven out of the 29 included studies presented costs per EDSS level in tables or figures, of which twelve presented costs by three categories of severity levels that we considered to be possible to extract \[[@pone.0159129.ref026], [@pone.0159129.ref033], [@pone.0159129.ref035], [@pone.0159129.ref037]--[@pone.0159129.ref043], [@pone.0159129.ref057], [@pone.0159129.ref058]\]. The levels of EDSS I, II, and III represent the categorization of different severities of MS, or case mix of MS, and this was reflected in the costs per patient that increased with higher levels of EDSS ([Table 5](#pone.0159129.t005){ref-type="table"}). Although absolute costs per patient varied highly between the studies, i.e., for EDSS II corresponding to 17,765 USD PPP \[[@pone.0159129.ref026]\] compared to 61,388 USD PPP \[[@pone.0159129.ref043]\], the costs ratios per patient (EDSS II and III compared to I) varied much less, i.e., 1.42 vs. 1.65, for Blahova Dusankova et al. \[[@pone.0159129.ref026]\] and Karampampa et al. \[[@pone.0159129.ref043]\], respectively ([Table 5](#pone.0159129.t005){ref-type="table"}). The coefficient of variation, defined as standard deviation compared to the mean, was 0.15 and 0.38, for EDSS II and III, respectively, for all 12 studies including EDSS estimates of costs. Concerning the mildest severity categorization, hereafter called EDSS I, seven out of ten studies that specified costs per category identified MS treatment as the main cost driver \[[@pone.0159129.ref026], [@pone.0159129.ref037]--[@pone.0159129.ref042]\]. The cost driver varied more between studies in the moderate severity group, EDSS II, where it was identified as drugs or MS treatment \[[@pone.0159129.ref037], [@pone.0159129.ref039]--[@pone.0159129.ref041]\], permanent reductions in productive work \[[@pone.0159129.ref026], [@pone.0159129.ref038], [@pone.0159129.ref043]\], other classifications of indirect costs \[[@pone.0159129.ref057], [@pone.0159129.ref058]\], and informal care \[[@pone.0159129.ref042]\]. Four out of ten studies \[[@pone.0159129.ref038], [@pone.0159129.ref040]--[@pone.0159129.ref042]\] identified informal care as the main cost driver for individuals in the most severe group, EDSS III, whereas four studies identified production losses due to permanent reductions in productive work \[[@pone.0159129.ref026], [@pone.0159129.ref037], [@pone.0159129.ref039], [@pone.0159129.ref043]\] and two identified other types of indirect costs \[[@pone.0159129.ref057], [@pone.0159129.ref058]\].

10.1371/journal.pone.0159129.t005

###### Annual cost per patient by EDSS classification group and cost ratios.
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  First author, country                                Year of cost   EDSS Classification   Annual cost per patient (USDPPP), recalculated at 2011 (1% inflation rate)   Cost ratio classification II vs. I   Cost ratio classification III vs. I                                    
  ---------------------------------------------------- -------------- --------------------- ---------------------------------------------------------------------------- ------------------------------------ ------------------------------------- -------- --------- ------------- -------------
  Auty \[[@pone.0159129.ref033]\], Canada              1995           ≤2.5                  3--6                                                                         ≥6.5                                 14 032                                20 964   35 771    1.50          2.50
  Dusankova \[[@pone.0159129.ref026]\], Czech Rep.     2007           0--3.5                4--6.5                                                                       7--9.5                               12 512                                17 765   28 902    1.42          2.31
  Henriksson \[[@pone.0159129.ref035]\], Sweden        1998           ≤3                    3.5--6                                                                       ≥6.5                                 18 966                                36 818   92 861    1.94          4.90
  Karampampa \[[@pone.0159129.ref038]\], Canada        2009           0--3                  4--6.5                                                                       7--9                                 26 155                                39 545   66 143    1.51          2.53
  Karampampa \[[@pone.0159129.ref037]\], France        2009           0--3                  4--6.5                                                                       7--9                                 19 041                                34 792   52 320    1.83          3.75
  Karampampa \[[@pone.0159129.ref040]\], Germany       2009           0--3                  4--6.5                                                                       7--9                                 26 795                                50 521   81 331    1.89          3.04
  Karampampa \[[@pone.0159129.ref039]\], Spain         2009           0--3                  4--6.5                                                                       7--9                                 29 819                                63 433   85 660    2.13          2.87
  Karampampa \[[@pone.0159129.ref042]\], UK            2009           0--3                  4--6.5                                                                       7--9                                 18 485                                40 424   92 135    2.19          4.98
  Karampampa \[[@pone.0159129.ref041]\], Italy         2009           0--3                  4--6.5                                                                       7--9                                 29 512                                54 300   52 020    1.84          1.76
  Karampampa \[[@pone.0159129.ref043]\], Netherlands   2011           0--3                  4--6.5                                                                       7--9                                 37 199                                61 388   120 801   1.65          3.25
  Orlewska \[[@pone.0159129.ref057]\], Poland          2002           \<3.5                 4--6                                                                         \>6.5                                15 720                                22 391   26 497    1.42          1.69
  Palmer \[[@pone.0159129.ref058]\], Australia         2010           1--3                  4--6                                                                         6.5--9                               24 389                                39 491   43 793    1.62          1.80
  **Mean (SD)**                                                                                                                                                                                               22 719                                40 153   64 853    1.75 (0.26)   2.86 (1.09)

The studies by Kobelt and colleagues represented about one third (10/29) of all included studies in our study. These studies used similar methodology but adapted to the different country settings: Inpatient care was used by between 6.7 to 25.8% of the included patients, sickness absence was used by 4.6 to 25%, and permanent reductions in productive work due to MS concerned 32.9 to 44.5% ([Table 6](#pone.0159129.t006){ref-type="table"}).

10.1371/journal.pone.0159129.t006

###### Resource use in studies by Kobelt and colleagues, recalculated to 12 months.
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  Country studied by Kobelt et al 2006   In-patient care (% of all)   In-patient days, average by hospitalized   Sickness absence[^1^](#t006fn001){ref-type="table-fn"} (% of all)   Sick-leave days (short term) among those with sickness absence[^1^](#t006fn001){ref-type="table-fn"}   Early retirement due to MS (% of all)
  -------------------------------------- ---------------------------- ------------------------------------------ ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------
  Austria                                25.8                         27.0                                       25.0                                                                17.3                                                                                                   44.5
  Belgium                                19.0                         27.5                                       8.8                                                                 17.0                                                                                                   32.9
  France (2009)                          17.0                         15.5                                       11.0                                                                21.5                                                                                                   ?
  Germany                                24.5                         21.0                                       11.0                                                                19.2                                                                                                   33.9
  Italy                                  15.6                         19.3                                       22.4                                                                10.3                                                                                                   33.3
  Netherlands                            7.9                          18.2                                       9.5                                                                 17.3                                                                                                   42.2
  Spain                                  17.0                         12.3                                       5.5                                                                 6.0                                                                                                    34.1
  Sweden                                 12.2                         21.6                                       10.2                                                                10.4                                                                                                   35.7
  Switzerland                            13.2                         38.0                                       4.6                                                                 11.0                                                                                                   33.9
  UK                                     6.7                          18.8                                       8.4                                                                 13.9                                                                                                   44.3

^1^ The definitions of sickness absences varies between studies or is not stated at all

Discussion {#sec008}
==========

There were large methodological variation between the identified studies and both costs and cost drivers appeared to be influenced by methodological choices. The main methodological differences were in the inclusion of different types of costs rather than the used perspective, as most studies used a BU approach and reported prevalence-based COI estimates. Moreover, implementation and categorization based on severity level differed largely between studies, Although absolute costs differed between studies, it appears that the cost ratios between different severity levels within studies were more stable, almost as 1 to 2 to 3 for EDSS I, II, and III, respectively. Our findings also suggest that cost drivers differ by severity level, where most studies showed that drug costs dominated in lower severity levels, while the main cost drivers in more severe levels of MS were production losses and informal care.

Methods of calculation affects the comparability between studies {#sec009}
----------------------------------------------------------------

Of the included studies on COI of MS, approximately 80% were published in the year 2000 or later, which indicates that studies of COI of MS can be described as a topic of recent and increasing interest. All included studies had a prevalence approach which can be used e.g., as a first step for calculations of cost effectiveness \[[@pone.0159129.ref019]\] of for example new drugs. However, if preventive interventions are in focus, an incidence approach would be more accurate \[[@pone.0159129.ref019], [@pone.0159129.ref021]\] to allow examination of costs over time \[[@pone.0159129.ref053]\]. An alternative method would be to create models based on retrieved or already published costs \[[@pone.0159129.ref068]\], and in two included studies such results were presented e.g., for 20-years \[[@pone.0159129.ref053]\] and life-time costs \[[@pone.0159129.ref033]\], in addition to the prevalence-based costs. Such analyses assume that the patterns of costs for different patients, age groups, and severity levels, based on a prevalence approach, can be used to estimate development in incidence-based cost over time.

According to our results from the 29 studies that were included for cost comparison, the one study using a TD approach reported the lowest mean cost per patient. It seems reasonable that the higher estimated COI for MS are, at least in parts, due to more cost components included in the calculation in BU studies. For instance, certain data may not be available in databases and by using the TD method, important cost data may be missing, e.g., costs related to complications where the disease of interest is not the main diagnosis \[[@pone.0159129.ref069]\]. Moreover, a potential reason for high costs when using a BU method is double counting of costs including the disease under study and its co-morbidities \[[@pone.0159129.ref069]\]. For instance, if some of the reported resource use assigned to MS actually were caused by a frequent co-morbidity to MS, such as depression \[[@pone.0159129.ref007], [@pone.0159129.ref070]\] the estimated COI will represent the costs for both MS and part of the costs for depression. Thus, a potentially estimated sum of costs for all diseases in a population may end up being higher than the total cost \[[@pone.0159129.ref071]\]. It would be preferable if future studies on COI of MS---as well as of other diagnoses---specified how resource utilization due to comorbidity was separated from that of the main diagnosis under study, in this case MS. Some comorbidities are independent from the studied disease, others a result of it. There are other examples of diseases for which it is not obvious if the COI for e.g., treatment of other diseases should be seen as related to the studied disease. One such example is diabetes where comorbidity has seen to incur high impact on total costs of illness \[[@pone.0159129.ref072]\].

Thus, it appears that the approaches of calculating costs of the included studies were not the main methodological differences, as all studies used the prevalence approach and almost all studies were BU. However, large variations were found regarding which costs that were included and in the handling of level of severity. Moreover, these aspects appear to be interlinked in their effect on cost drivers and overall costs.

Over time, it has become increasingly common to assess MS costs according to disease severity (i.e., EDSS). Our finding that costs increase with increasing disability level is consistent with the results of previously conducted reviews of COI of MS \[[@pone.0159129.ref007], [@pone.0159129.ref009]--[@pone.0159129.ref011]\]. Similar to the findings by Naci and colleagues \[[@pone.0159129.ref007]\], many studies showed that medical costs corresponded to a greater proportion at a lower severity level, while the proportion of non-medical direct costs and indirect costs increased with severity of disease. The relative relationship between costs in different severity levels has been examined previously \[[@pone.0159129.ref010], [@pone.0159129.ref011]\], whereas a review including ten studies (the most recent published in 2002) showed that the relative costs were more consistent, since the absolute costs depend on a number of contextual factors \[[@pone.0159129.ref010]\].

Knowledge of the different distributions of cost components between severity levels has implications for studies of MS treatments. Due to how patients are recruited to e.g., clinical trials of new treatments, a large proportion of the included patients may have a mild disease severity level and recently diagnosed MS, or have had complications to previous treatments. If patients with less severe disease are dominant, this distributional effect will result in the estimated costs for drugs being overestimated as compared to other cost components. It is thus difficult to conclude, based on such studies what the possible savings for introducing new drugs in the population are. Moreover, the health status of a patient having MS may possibly in a longer perspective deteriorate, which should be associated also with the effectiveness of given treatment, and thus result in higher indirect costs. Although other research methods are needed to estimate the economic impact of insufficient treatment effects over time, our results indicate that costs per patient may double and later triple by EDSS level.

Contextual differences may cause comparisons of COI studies of MS unfeasible, such as differences in categorization of costs and resource use. It has e.g., been argued that there might be contextual differences for patients with MS to rely on family members or on friends for informal care, which can also affect the calculated cost for informal care \[[@pone.0159129.ref051]\]. As the included studies categorized informal care as an unspecified direct cost \[[@pone.0159129.ref027], [@pone.0159129.ref034], [@pone.0159129.ref035], [@pone.0159129.ref052], [@pone.0159129.ref053]\], as a direct non-medical cost \[[@pone.0159129.ref037]--[@pone.0159129.ref051], [@pone.0159129.ref053]\], presented separately from direct and indirect costs \[[@pone.0159129.ref058]\] or, as an indirect cost \[[@pone.0159129.ref026], [@pone.0159129.ref057]\], Included cost categories, as well as e.g., proportions will differ due to methodological choices.

Moreover, laws and attitudes towards use of social insurances such as full-time or part-time disability pension or early retirement for patients with MS differs between countries \[[@pone.0159129.ref027]\], as well as how sickness absence and disability pension are described and/or measured. For instance, it is often not clear if 'short-term sickness absence' means e.g., \<7 days or \<90 days. Also, disability pension or what in some studies is called early retirement or early retirement due to MS, is seldom clearly defined. There is probably a difference between taking old-age pension early due to health problems and being granted disability pension. Previous reviews on sick leave and disability pension have pointed out the lack of clarity in how different concepts are used \[[@pone.0159129.ref073], [@pone.0159129.ref074]\]. There are also variations in organization of healthcare which may lead to differences in consumption of care but also in prices for resources of healthcare \[[@pone.0159129.ref025]\]. Applying estimates from studies in one population that differs from the population of interest may also cause problems for comparisons \[[@pone.0159129.ref008]\], as well as differences in cut-off points used for the EDSS \[[@pone.0159129.ref052]\]. In addition, the length of study period, e.g., one month compared to six months, may lead to inaccuracies or biases when the results are multiplied up to annual costs \[[@pone.0159129.ref061]\].

Furthermore, above described methodological and contextual differences probably have had an impact on what could be considered as the main cost driver. The severity of MS might differ within patient groups which add to differences of resource utilization making healthcare costs skewed \[[@pone.0159129.ref075]\]. Age, disability (EDSS), and presence of depression have been found to be independent predictors of costs in univariate analyses \[[@pone.0159129.ref059]\]. Furthermore, differences between studies as regards the proportion of patients with MS relapses of severity, as well as duration of relapses, are important for the estimated economic burden of MS \[[@pone.0159129.ref007]\], and differences in sampling of patients for inclusion COI studies may also be of importance for comparison between studies \[[@pone.0159129.ref050]\]. Questions in need of answer in connection to the (more common) BU method are several: were the patients included representative of the MS population, were the resource use reported by the patients accurate (e.g., do patients to the same extent report hospitalizations and use of over-the-counter medications during the last year or month), as well as correctly interpreted \[[@pone.0159129.ref052]\]. Although the same methodology was described, the response rates generally were low and differed between 16 to 52% in the nine studies by Kobelt and colleagues \[[@pone.0159129.ref025], [@pone.0159129.ref044]--[@pone.0159129.ref051]\], which could be a source of bias and affect the reliability of results \[[@pone.0159129.ref035]\].

What could be done to promote comparability of COI studies? One suggested solution is to give support to well-designed multinational prospective studies that could enhance the understanding of possible differences between studies \[[@pone.0159129.ref076]\]. An important step would be to ensure that included costs and concepts are clearly defined and described in relation to the healthcare system under study, so that readers are able to judge the applicability of results to their own settings.

Strengths and limitations {#sec010}
-------------------------

This systematic review used a novel approach by step by step selection of more similar studies for comparison, thus indication in each step the remaining methodological differences. To our knowledge, this is the first review of the COI of MS using this approach.

The mapping of published studies that describes methods used for calculations of COI of MS made the analysis of comparing costs feasible, enabling comparisons between the COI studies of MS based on cost ratios for severity of MS according to the EDSS index. However, the mapping only entails some of the methodological differences and we acknowledge that the comparison between disease severity levels within studies provides more information than the comparison between studies. In previous reviews \[[@pone.0159129.ref010], [@pone.0159129.ref011]\], the relative relationship has been studied by using the approach of examining each disability level on the EDSS scale in relation to the average of the lowest EDSS category, which differs from our approach of comparing between mild, moderate and severe MS. This categorization of the EDSS was implemented to facilitate comparison between studies also when costs were not reported on every EDSS score in all studies. Although the cut offs for EDSS were not defined by exactly the same EDSS scores in the twelve studies included in that comparison, ratios of costs tended to increase at a rather similar rate as 1 to 1.75 to 2.86, or almost as 1 to 2 to 3, from the least to the most severe group of MS disease, and with limited deviations between the cost ratios of included studies. Although not possible to extract from the series of studies by Kobelt and colleagues \[[@pone.0159129.ref025], [@pone.0159129.ref044]--[@pone.0159129.ref052]\], these studies stated clearly that costs were greater following higher disease severity, which further emphasizes the relevance of this association between costs and severity of MS.

The full-text reading was independently performed by two authors. One limitation of the literature search was that the title and abstract examination was performed by one author, thus in this stage not having the possibility to discuss potential disagreement of relevant studies with another author. However, all studies mentioning economic burden related to MS were included for full-text reading. In order to find possibilities of comparisons, the included studies in our review were based on data from OECD-countries. This fact and the finding that 59% of the included studies were undertaken by two groups of authors with connections to research in Sweden might be interpreted as a kind of bias. However, as comparisons of outcome of ratios of costs of EDSS-levels ([Table 5](#pone.0159129.t005){ref-type="table"}) show, there were high resemblances of outcome between all included studies. The restriction to OECD-countries was a consequence of the method chosen for recalculations of costs i.e., using the PPP of the OECD \[[@pone.0159129.ref023]\], which facilitated comparison between study results. The highest and lowest cost estimates were reported by two of the studies that were handled differently in the PPP calculations ([Fig 2](#pone.0159129.g002){ref-type="fig"}), which indicates the difficulties in translating costs over time and between years. After excluding these two studies, the average total cost per patient and year ranged from USD 24 666 to USD 51 678 (PPP). Furthermore, the choice of annual inflation rate will impact the comparison between studies using different years of price level, where a higher rate would reduce differences of the average total cost between compared studies.

Due to the exclusion of intangible costs in this review, we underestimate the economic impact of MS in society. According to previous research, intangible costs represented up to 50% of the overall costs of MS \[[@pone.0159129.ref014]\] depending on methodological choices in the original publications. Among the studies included in our study comparison, only eleven studies \[[@pone.0159129.ref025], [@pone.0159129.ref035], [@pone.0159129.ref044]--[@pone.0159129.ref052]\] included intangible costs. Additionally, as our findings were based on studies using mainly patient questionnaires and self-selected samples, further studies of costs resulting from MS in representative population-based samples are warranted.

Conclusion {#sec011}
==========

Although similar perspectives were applied used in the included studies, our findings support the raised concern of that results regarding the total cost per patient and year varies greatly between studies, and this was mainly due to differences in which costs that were included and how severity of disease was handled. As expected, the total costs increase with higher level of disease severity. However, we also found that the distribution of cost components varied with severity level. Although great variations between studies were found in terms of absolute costs, the relative costs expressed as cost ratios comparing different levels of severity level of MS indicated resemblances, appearing to make comparisons between studies feasible.
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